The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks ...

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

On Monday, Moderna published the results of a late-stage study of mRNA-1010, its seasonal flu vaccine. In a phase 3 clinical ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

The decision to cancel the Moderna contracts, undoubtedly driven by anti-vaccine crusader and HHS Secretary Robert F. Kennedy, Jr., puts the entire nation at risk, as does this administration’s ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...